JPRN-jRCT2080220904
Unknown
Phase 3
Phase 3, multicenter, open-label study to evaluate the safety and efficacy of long-term administration of TAK-085 to the patients with hypertriglyceridemia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Takeda Pharmaceutical Company Limited
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects diagnosed with hypertriglyceridemia, etc.
Exclusion Criteria
- •1\. Subject had coronary artery disease
- •2\. Subject received aortic aneurysmectomy
- •3\. Subject had hemorrhagic disease etc.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.EUCTR2013-000799-14-BEovalon S. A.142
Active, not recruiting
Phase 1
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.EUCTR2019-000593-32-DEovalon S.A.142
Completed
Phase 3
Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostate cancerprostate adenocarcinomaprostate cancer10038597NL-OMON42816ovalon S.A.12
Active, not recruiting
Phase 1
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.Prostate cancerMedDRA version: 18.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000799-14-NLovalon S. A.142
Active, not recruiting
Phase 1
Phase III, open-label, multi-centre study to investigate the movement, effect and safety of Zoreline 3.6 mg goserelin implant (Novalon) injected under skin, in women with confirmed endometriosisEndometriosisMedDRA version: 19.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersTherapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2013-000798-59-HUovalon S.A142